Osteoporosis is the most prevailing disease in postmenopausal women leading to increased risk of fractures, pain and low quality of life. It is a progressive bone disease which remains unnoticed until a fracture occurs. The disease is more predominant in older age population particularly females due to reduced estrogen levels and limited calcium absorption. The cost burden of treating osteoporotic fractures is too expensive therefore primary focus should be treatment at an early stage. Most of the marketed drugs are available as oral delivery dosage forms.